The Bone Loss That Happens Before You Feel Anything — And Why the Window Around Menopause Matters

Here is the uncomfortable thing about bone loss: there is no warning sign.

No ache, no moment where the body registers something shifting, no signal that anything has changed. Bone loss in the years around menopause is silent in a way that most health changes are not. The first sign, for too many women, is a fracture from a fall that should not have caused one.

That silence is worth addressing directly and early — not with fear, but with the kind of quiet attention that silent problems are easiest to give before they become visible ones.

Here is what the research shows about what is happening, when it starts, and what the window around menopause specifically means for bone health long term.

What estrogen actually does for bone

Bone is living tissue. It is constantly in a state of remodelling: old bone is broken down by cells called osteoclasts, and new bone is built by cells called osteoblasts. In a healthy adult in reproductive years, this process is roughly in balance — the breakdown rate and the build rate are matched, so overall bone density stays relatively stable.

Estrogen keeps this balance by restraining osteoclast activity. It acts as a brake on the breakdown side of the equation. When estrogen levels are stable and adequate, the brakes hold and the remodelling process stays in balance.

When estrogen begins to decline — which starts in perimenopause, typically in the early-to-mid 40s, well before menopause itself — the brake weakens. Osteoclasts become more active. The breakdown rate accelerates while the build rate remains the same or declines. The result is a net negative: more bone is being lost than is being replaced.

This is not a dramatic process. It is measured in fractions of a percent per year. But those fractions compound. By the time of the menopause transition, some women have already lost 10-20% of their peak bone density — mostly silently, mostly without any symptoms, in the decade before they expected menopause to be relevant.

Why the window around menopause matters specifically

Bone loss accelerates significantly in the first five years after menopause. This is the window where the decline is fastest, where the compounding happens most rapidly, and where the gap between intervention and inaction is most consequential.

Bone that is lost in this window is difficult to recover. The osteoblast activity that builds new bone becomes less responsive with age. What is built later does not fully compensate for what was lost earlier. This is why the approach to bone health is most effective when it begins before significant loss has occurred — during perimenopause and the early transition, rather than after a diagnosis has been made.

Peak bone density, reached in the late 20s and early 30s, is the reserve the body draws down from in the decades that follow. Women who entered perimenopause with higher peak density have more reserve to draw from. Women with lower peak density have less margin. Both groups are affected by the hormonal transition; the starting point changes how much the acceleration matters.

What a DEXA scan actually tells you

The standard tool for measuring bone density is a DEXA scan (dual-energy X-ray absorptiometry). It produces a T-score that compares your bone density to the average peak bone density of a healthy young adult. A T-score above -1.0 is considered normal. Between -1.0 and -2.5 is classified as osteopaenia — lower than optimal but not yet in the osteoporosis range. Below -2.5 is osteoporosis.

The limitation of waiting for a DEXA scan to flag a problem is that osteopaenia and early osteoporosis are both silent — the scan finds something that has already been happening for years. The scan is a snapshot, not a predictor. What matters more than the single score is the trajectory: is the rate of loss accelerating, stable, or slowing?

A baseline scan before or during perimenopause, followed by a repeat scan two to three years later, tells you the rate of change. That rate is more actionable than a single number.

What the research supports for bone health in this decade

Exercise is the most effective non-pharmaceutical intervention for bone density. Weight-bearing and resistance exercise specifically — walking on varied terrain, strength training, impact activities where joints allow — apply mechanical load to bone, which stimulates osteoblast activity and supports the building side of the remodelling equation. Swimming and cycling, while excellent for overall health, are non-weight-bearing and have minimal effect on bone density.

Calcium, vitamin D, magnesium, and vitamin K2 form the nutritional stack with the most consistent evidence for supporting bone health. Calcium provides the raw material; vitamin D governs how much of it is absorbed; magnesium is required for vitamin D activation and osteoblast function; vitamin K2 directs calcium into bone rather than soft tissue. Each is necessary; none is sufficient alone.

The research on collagen and bone tissue has grown substantially in the past decade. Bone is approximately 30% collagen by weight, providing the structural matrix that calcium mineralises. Collagen peptide supplementation has shown effects on bone density markers in several clinical trials, particularly when combined with adequate calcium and vitamin D. The evidence is not as established as for calcium and vitamin D, but it is more specific and more consistent than the general collagen-for-joint-health literature.

The bone density article on this site covers what the research says about supplementation specifically — including which forms of calcium absorb better, what vitamin K2 does that the other nutrients don’t, and who the evidence most strongly applies to: Bone Density After Menopause: What the Research Says About Supplements.

HRT, where appropriate and prescribed, has a direct and significant bone-protective effect. The clinical decision about HRT involves individual risk factors that are outside the scope of this article. But bone density is one of the well-documented benefits and is worth raising in the HRT conversation if it hasn’t been.

The conversation worth starting now

If you are in your 40s and have not discussed bone density with your GP, it is worth raising. A baseline DEXA scan before the menopause transition gives you the starting point. Knowing your risk factors — family history, previous fractures, smoking history, long-term corticosteroid use, low body weight — allows the conversation to be specific rather than general.

None of this requires alarm. Bone loss in perimenopause is a normal physiological process that the right inputs can meaningfully slow. The window to give it the most attention is before significant loss has accumulated — which is now, for most women reading this.